190 related articles for article (PubMed ID: 29949158)
1. Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo.
Teng JP; Yang ZY; Zhu YM; Ni D; Zhu ZJ; Li XQ
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3819-3825. PubMed ID: 29949158
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
Tang CH; Liu XQ; Yang SF; Zhu B; Gao HJ
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
He SW; Zhang Y; Chen L; Luo WJ; Li XM; Chen Y; Huang SY; He QM; Yang XJ; Li YQ; Liu N; Zhao Y; Ma J
FASEB J; 2021 Oct; 35(10):e21885. PubMed ID: 34478585
[TBL] [Abstract][Full Text] [Related]
4. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
5. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
6. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
[No Abstract] [Full Text] [Related]
7. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
8. Propofol Improves Sensitivity of Lung Cancer Cells to Cisplatin and Its Mechanism.
Huang Y; Lei L; Liu Y
Med Sci Monit; 2020 Mar; 26():e919786. PubMed ID: 32225124
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
[TBL] [Abstract][Full Text] [Related]
10. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
He L; Du ZD; Wang Y; Meng RQ; Zhao WW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
[TBL] [Abstract][Full Text] [Related]
11. Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Chougule MB; Patel A; Sachdeva P; Jackson T; Singh M
PLoS One; 2011; 6(11):e27394. PubMed ID: 22102891
[TBL] [Abstract][Full Text] [Related]
12. Experimental study of combination therapy with S-1 against pancreatic cancer.
Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
[TBL] [Abstract][Full Text] [Related]
13. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
[TBL] [Abstract][Full Text] [Related]
14. [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].
Zhong H; Zuo Y; Wu X; Peng Y; He H; Yang J; Guan C; Xu Z
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):805-812. PubMed ID: 27978865
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
16. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
17. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
19. Role of dalteparin sodium on the growth of cancer cells and tumor-associated angiogenesis in A549 human lung cancer cell line and grafted mouse model.
Rui Y; Wang D; Hu D; Huang L
J Cancer Res Ther; 2018 Dec; 14(Supplement):S985-S992. PubMed ID: 30539834
[TBL] [Abstract][Full Text] [Related]
20. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]